Medtronic plc (MDT) Stock Price: $81.98+1.29 (+1.60%)
The total return cagr for Medtronic plc (MDT) stock is -3.29% over the past 12 months. The 3 year average growth rate is 2.58% and the 5 year cagr is -4.95%. Total return includes dividends reinvested.
The closing share price for Medtronic plc (MDT) stock was $81.98 for Tuesday, June 9, 2026, up +1.60% from the previous day.
MDT Price Chart
MDT Key Metrics
See All MetricsMDT Earnings Preview
Next Earnings Date
Aug 18, 2026
70 days away
EPS Estimate
1.39
Revenue Est.
$9.56B
Last Quarter Results
EPS
$1.55
vs Estimate
$1.54
Revenue
$9.81B
vs Estimate
$9.62B
MDT Analyst Ratings
Consensus Rating
Based on 26 analysts
Average Price Target
$98.58
+20.2% upside
Low
$78.00
Current
$81.98
High
$121.00
MDT Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q3 2026 | N/A | $1.39 | N/A | 16 |
| Q4 2026 | N/A | $1.35 | N/A | 16 |
| Q1 2027 | N/A | $1.43 | N/A | 11 |
| Q2 2027 | N/A | $1.78 | N/A | 7 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2028 | N/A | $6.39 | N/A | 15 |
| FY 2029 | N/A | $6.95 | N/A | 4 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q3 2026 | N/A | $9.56B | N/A | 16 |
| Q4 2026 | N/A | $9.49B | N/A | 16 |
| Q1 2027 | N/A | $9.56B | N/A | 11 |
| Q2 2027 | N/A | $10.31B | N/A | 7 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2028 | N/A | $39.98B | N/A | 15 |
| FY 2029 | N/A | $41.64B | N/A | 4 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
MDT Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1MDT | $105.25B | $81.98 | +1.60% | -3.29% | -4.95% | +2.19% |
MDT Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha